Noxxon reveals results from PHASE 1/2 trial of NOX-A12/KEYTRUDA®
Category: #health  By Mateen Dalal  Date: 2019-10-01
  • share
  • Twitter
  • Facebook
  • LinkedIn

Noxxon reveals results from PHASE 1/2 trial of NOX-A12/KEYTRUDA®

Colorectal cancer (CRC), also known as bowel or colon cancer, is a type of cancer that involves abnormal growth of cells that can invade or spread to other parts of the body. Growing prevalence of CRC has led various pharmaceuticals firms to develop novel drugs using advanced research and clinical trials.

NOXXON Pharma N.V. is one such firm that develops innovative cancer treatments and has recently announced new clinical findings from the Phase 1/2 trial of NOX-A12 paired with Keytruda® (pembrolizumab) in patients suffering from microsatellite-stable, metastatic colorectal and pancreatic cancer.

Reportedly, the data was presented at the ESMO (European Society for Medical Oncology) Congress 2019, held in Spain.

According to reliable sources, the combination of pembrolizumab and NOX-A12 showed stable disease in 25% of patients, induced an immune response and sustained time on treatment, compared to previous therapy for 35% of patients. Moreover, constant follow-up of patients has established an overall survival statistic of 22% at 12 months and 42% at 6 months.

Speaking on the development, Aram Mangasarian, CEO, NOXXON, said that both metastatic pancreatic and colorectal cancers have a very limited remedial alternative. However, the positive results from the clinical data and the fact that three heavily pre-treated patients lived over a year reinforces the capability of NOX-A12 to target the tumor microenvironment.

Incidentally, in addition to the positive outcomes, the company has also prior achieved a monumental landmark when it completed the capital increase of €1 million which was previously halted. Noxxon has also revealed that its future investments are fixed for the upcoming investment round.

Commenting on the attained capital, Mangasarian said that the company is delighted to reveal the conclusion of the capital increase which has positioned itself at a secure position which would ensure the progression and beginning of Phase 1/2 clinical study in brain cancer.

Noxxon is also dedicated towards building the clinical studies sites in Germany where the trial was given a green signal by the Ethics Committees and regulatory authorities, he added.

Source Credit: https://www.noxxon.com/downloads/pressrel/2019-09-29_ESMO_Poster_PR_EN.pdf

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
By Mateen Dalal

Air France–KLM S.A., one of the leading global air transport players, has reportedly made a proposal to invest in Malaysia Airlines and gain around 49 percent stake. Japan Airlines (JAL) is also looking to acquire a 25 percent stake in Mal...

Accenture opens innovation center in South Beach Road office
Accenture opens innovation center in South Beach Road office
By Mateen Dalal

Accenture, an Irish multinational professional services company, has recently opened a global innovation center within the Accenture’s office at South Beach Road, which is supported by EDB (Economic Development Board) in Singapore. It will pro...

Verrica unveils positive data from VP-102 study in molluscum treatment
Verrica unveils positive data from VP-102 study in molluscum treatment
By Mateen Dalal

Findings from the study are being produced at the 17th Annual Winter Clinical Dermatology Conference in Kohala Coast The data indicated a considerable increase in the percentage of patients with lesion clearance in VP-102 group Verrica Pharmaceu...